Valuation : Enliven Therapeutics, Inc.

Market Cap 4.12B 3.55B 3.36B 3.05B 5.72B 394B 5.74B 39.92B 15.35B 200B 15.47B 15.13B 633B P/E 2026 *
-30.4x
P/E 2027 * -24.5x
Enterprise Value 3.72B 3.21B 3.04B 2.75B 5.16B 356B 5.19B 36.06B 13.87B 181B 13.98B 13.67B 572B EV / Sales 2026 *
-
EV / Sales 2027 * 571,122x
Free-Float
93.78%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Enliven Therapeutics, Inc.

1 day-3.36%
1 week-8.40%
Current month-6.13%
1 month-7.55%
3 months+34.64%
6 months+77.00%
Current year+252.86%
1 week 54.12
Extreme 54.12
59.96
1 month 54.12
Extreme 54.12
62
Current year 14.78
Extreme 14.785
62.32
1 year 14.78
Extreme 14.785
62.32
3 years 9.8
Extreme 9.8
62.32
5 years 9.8
Extreme 9.8
62.32
10 years 9.8
Extreme 9.8
62.32
Manager TitleAgeSince
Chief Operating Officer 46 2023-02-22
Chief Executive Officer 57 2025-12-10
Chief Tech/Sci/R&D Officer 61 2023-02-22
Director TitleAgeSince
Director/Board Member 63 2023-02-22
Director/Board Member 48 2023-02-22
Director/Board Member 48 2023-02-22
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Exercice

Chief Technology Officer

15,000 0.0210%
8/17/26 Sell

Chief Financial Officer

-6,018 0.0084%
8/4/26 Exercice

Director

476,385 0.6668%
Change 5-day change 1-year change 3-year change Capi.($)
-3.45%-8.40%+172.79%+225.97% 4.12B
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-6.42%+30.19%+76.15% 62.23B
+1.70%+2.23%-11.44%+387.21% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.48%-6.58%-7.07%-17.82% 24.22B
+0.43%-4.78%+18.26%-20.61% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.27%-4.42%+44.36%+156.49% 14.23B
Average -1.11%-4.14%+49.90%+177.45% 27.68B
Weighted average by Cap. -0.88%-3.83%+35.19%+138.00%

Financials

2026 *2027 *
Net sales - 6.25K 5.39K 5.1K 4.62K 8.67K 597K 8.71K 60.56K 23.29K 304K 23.47K 22.96K 960K
Net income -126M -109M -103M -93.53M -175M -12.08B -176M -1.23B -471M -6.15B -475M -465M -19.43B -172M -148M -140M -127M -238M -16.4B -239M -1.66B -640M -8.34B -645M -630M -26.36B
Net Debt -398M -343M -325M -294M -552M -38.02B -555M -3.86B -1.48B -19.34B -1.49B -1.46B -61.13B -551M -474M -449M -407M -764M -52.59B -768M -5.33B -2.05B -26.76B -2.07B -2.02B -84.55B
Logo Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
Employees
67
Date Price Change Volume
26-09-11 US$54.41 -3.25% 665,906
26-09-10 US$56.23 -2.12% 769,641
26-09-09 US$57.45 -3.23% 1,293,938
26-09-08 US$59.37 +0.08% 1,325,966
26-09-04 US$59.32 -0.55% 1,113,062
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
56.23USD
Average target price
73.90USD
Spread / Average Target
+31.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELVN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!